

Connecting via Winsock to STN

Welcome to STN International! Enter xix

LOGINID:sssptal600txm

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS 1 Web Page for STN Seminar Schedule - N. America
 NEWS 2 AUG 15 CACLD to be discontinued on December 31, 2008
 NEWS 3 OCT 07 EPFULL enhanced with full implementation of EPC2000
 NEWS 4 OCT 07 Multiple databases enhanced for more flexible patent
 number searching
 NEWS 5 OCT 22 Current-awareness alert (SDI) setup and editing
 enhanced
 NEWS 6 OCT 22 WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT
 Applications
 NEWS 7 OCT 24 CHEMLIST enhanced with intermediate list of
 pre-registered REACH substances
 NEWS 8 NOV 21 CAS patent coverage to include exemplified prophetic
 substances identified in English-, French-, German-,
 and Japanese-language basic patents from 2004-present
 NEWS 9 NOV 26 MARPAT enhanced with FSORT command
 NEWS 10 NOV 26 MEDLINE year-end processing temporarily halts
 availability of new fully-indexed citations
 NEWS 11 NOV 26 CHEMSAFE now available on STN Easy
 NEWS 12 NOV 26 Two new SET commands increase convenience of STN
 searching
 NEWS 13 DEC 01 ChemPort single article sales feature unavailable
 NEWS 14 DEC 12 GBFULL now offers single source for full-text
 coverage of complete UK patent families

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
 AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN Welcome Banner and News Items
 NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
 specific topic.

All use of STN is subject to the provisions of the STN Customer
 agreement. Please note that this agreement limits use to scientific
 research. Use for software development or design or implementation
 of commercial gateways or other similar uses is prohibited and may
 result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 21:44:09 ON 15 DEC 2008

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 21:44:16 ON 15 DEC 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

10/566,585

STRUCTURE FILE UPDATES: 14 DEC 2008 HIGHEST RN 1064385-33-0
DICTIONARY FILE UPDATES: 14 DEC 2008 HIGHEST RN 1064385-33-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10565585.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 21:45:17 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 269 TO ITERATE

100.0% PROCESSED 269 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 4396 TO 6364
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 21:45:21 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 5392 TO ITERATE

100.0% PROCESSED 5392 ITERATIONS 10 ANSWERS
SEARCH TIME: 00.00.01

L3 10 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 178.36 178.57

FILE 'CAPLUS' ENTERED AT 21:45:24 ON 15 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is

strictly prohibited.

FILE COVERED 1907 - 15 Dec 2008 VOL 149 ISS 25
 FILE LAST UPDATED: 14 Dec 2008 (20081214/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s 13

L4 5 L3

=> d bib abs hitstr 1-5 14

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:912445 CAPLUS

DN 145:285163

TI Pharmaceutical compositions containing N-glucoside compounds

IN Nomura, Sumihiko; Sakamoto, Toshiaki; Ueda, Kiichiro

PA Tanabe Sanyaku Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 30pp.


CODEN: JKXKXAF

DT Patent

LA Japanese

FAV.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2006232825	A	20060907	JP 2006-19935	20060130
PRAI	JP 2005-23727	A	20050131		
OS	MAPPAT 145:285165				
GI					



AB The invention relates to a pharmaceutical composition characterized by containing a compound I (ring A and B are (un)substituted monocycle unsatd. hetero rings, etc.; R = H, lower alkyl, lower alkenyl, lower alkoxy, lower alkoxy carbonyl) or its salt or prodrug as an active component, suitable for use for treatment and/or prevention of diabetes or obesity. For example, 2-(4-ethylbenzyl)-N-(β-D-glucopyranosyl)aniline was prepared, and examined for its inhibitory effect on SGLT 2 (sodium-dependent glucose transporter 2) *in vitro*.

IT 841236-78-OP 841236-79-1P 841236-80-4P

841236-81-5P 841236-82-6P

RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(pharmaceutical compns. containing N-glucoside compds. for treatment of diabetes, obesity, and related diseases)

RN 841236-78-0 CAPLUS

CN β-D-Glucopyranosylamine, N-[2-[(4-ethylphenyl)methyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.


10/566,585



RN 841236-79-1 CAPLUS

CN β -D-Glucopyranosylamine, N-[2-[(4-ethylphenyl)methyl]-4-(trifluoromethyl)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 841236-80-4 CAPLUS

CN β -D-Glucopyranosylamine, N-[2-(phenylmethyl)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 841236-81-5 CAPLUS


CN β -D-Glucopyranosylamine, N-[2-[(4-ethylphenyl)methyl]-4-fluorophenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 841236-82-6 CAPLUS
 CN β-D-Glucopyranosylamine, N-[(4-ethylphenyl)methyl]-3,4-difluorophenyl- (CA INDEX NAME)



Absolute stereochemistry.



L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2005:120945 CAPLUS
 DN 142:219494
 TI Preparation of aryl-aminodeoxy monosaccharides as antidiabetic agents
 IN Nomura, Sumihiro; Sakamoto, Toshiaki; Ueta, Kiichiro
 PA Tanabe Selyaku Co., Ltd., Japan
 SO PCT Int. Appl., 62 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CWT 8

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005012321	A1	20050210	WO 2004-JP11311	20040730
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DT, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SN, TM, TN, TR, TT, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RM: BM, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004260760	A1	20050210	AU 2004-260760	20040730
CA 2534022	A1	20050210	CA 2004-2534022	20040730
EP 1654269	A1	20060510	EP 2004-771313	20040730
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, FI, IE, SI, PL, RO, CY, TR, BG, CZ, EE, HU, PT, SK				
CN 1829728	A	20060906	CN 2004-80022006	20040730
BR 2004013233	A	20061003	BR 2004-13233	20040730
JP 2007518682	T	20070712	JP 2006-519250	20040730
NO 2006000219	A	20060428	NO 2006-219	20060116

	MX 2006PA01273	A	20060411	MX 2006-PA1273	20060131
	KR 2006132539	A	20061221	KR 2006-702158	20060131
	IN 2006CN00723	A	20070629	IN 2006-CN723	20060228
	US 20060217323	A1	20060908	US 2006-446014	20060602
	US 20060229260	A1	20061012	US 2006-453728	20060615
	US 20060234954	A1	20061019	US 2006-453727	20060615
	US 20060293251	A1	20061228	US 2006-453726	20060615
	US 20070060545	A1	20070315	US 2006-566585	20060728
	AU 2008200240	A1	20080207	AU 2008-200240	20080117
PRAI	US 2003-491523P	P	20030801		
	US 2003-491534P	P	20030801		
	US 2003-519155P	P	20031112		
	US 2003-519209P	P	20031112		
	US 2003-519210P	P	20031112		
	US 2003-519381P	P	20031112		
	US 2004-579722P	P	20040615		
	US 2004-579730P	P	20040615		
	US 2004-579758P	P	20040615		
	US 2004-579792P	P	20040615		
	AU 2004-260761	A3	20040730		
	US 2004-903034	A3	20040730		
	US 2004-903136	A3	20040730		
	US 2004-903233	A3	20040730		
	US 2004-903234	A3	20040730		
	WO 2004-JP11311	W	20040730		
OS	CASREACT 142:219494; MARPAT 142:219494				
GI					



AB Aryl-aminodeoxy monosaccharides I, wherein A and B are (1) A is an optionally substituted unsatd. monocyclic heterocyclic, and B is an optionally substituted unsatd. monocyclic heterocyclic, an optionally substituted unsatd. fused hetero-bicyclic, or an optionally substituted benzene, (2) A is an optionally substituted benzene, and B is an optionally substituted unsatd. monocyclic heterocyclic, an optionally substituted unsatd. fused hetero-bicyclic, or an optionally substituted benzene, or (3) A is an optionally substituted unsatd. fused hetero-bicyclic, wherein -NR- group and -CH₂- group are both on the same of the unsatd. fused hetero-bicyclic, and B is an optionally substituted monocyclic unsatd. heterocyclic, an optionally substituted unsatd. fused hetero-bicyclic, or an optionally substituted benzene; and R is a hydrogen atom, a lower alkyl group, a lower alkanoyl group or a lower alkoxyalkyl group, or a pharmaceutically acceptable salt thereof, or a prodrug thereof. A method is claimed for treatment of type 1 and 2 diabetes mellitus, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of the compound, or in combination with another antidiabetic agent, an agent for treating diabetic complications, an anti-obesity agent, an antihypertensive agent, an antiplatelet agent, an anti-atherosclerotic agent and/or a hypolipidemic agent. Thus, title II was prepared and tested as an antidiabetic agent. The dosage of the present compd.s or a pharmaceutically acceptable salt thereof may vary according to the administration routes, ages, body weight, conditions of a patient, or kinds and severity of a disease to be treated, and it is usually in the range of about 0.1 to 50 mg/kg/day, preferably in the range of about 0.1 to 30 mg/kg/day.

II 841236-78-OP 841236-79-1P 841236-80-4P

841236-81-5P 841236-82-6P


RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

RN (Preparation of aryl-aminodeoxy monosaccharides as antidiabetic agents)

RN 841236-78-0 CAPLUS

CN β -D-Glucopyranosylamine, N-[2-[(4-ethylphenyl)methyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 841236-79-1 CAPLUS

CN β -D-Glucopyranosylamine, N-[2-[(4-ethylphenyl)methyl]-4-(trifluoromethyl)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 841236-80-4 CAPLUS

CN β -D-Glucopyranosylamine, N-[2-(phenylmethyl)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 841236-81-5 CAPLUS

CN β -D-Glucopyranosylamine, N-[2-[(4-ethylphenyl)methyl]-4-fluorophenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 841236-82-6 CAPLUS

CN β -D-Glucopyranosylamine, N-[(2-[(4-ethylphenyl)methyl]-3,4-difluorophenyl)-] (CA INDEX NAME)

Absolute stereochemistry.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1998:489174 CAPLUS

DN 129:197547

OREF 129:39947a,39950a

TI Isolation and identification of bromfenac glucoside from rat bile
 AU Kirkman, Sandra K.; Zhang, Mei-Yi; Horwath, Peter M.; Scatina, JoAnn
 CS Drug Safety and Metabolism Div., Wyeth-Ayerst Res., USA
 SO Drug Metabolism and Disposition (1998), 26(7), 720-723
 CODEN: DMDSD7; ISSN: 0090-9556

PB Williams & Wilkins

DT Journal

LA English

AB Bromfenac (Duract), a drug approved for pain, was expected to be metabolized by the rat to an acyl glucuronide, a metabolite formed with most comds. of similar structure. During the investigation of metabolite profiles in rat bile following administration of 1 mg/kg i.v. doses of 14C-bromfenac, an acid-labile metabolite was found that degraded to form 14C-bromfenac. Isolation and characterization of this metabolite indicated that it is an unusual conjugate, bromfenac N-glucoside.


IT 212266-82-5P

RI: ANT (Analyte); BSU (Biological study, unclassified); MFM (Metabolic formation); PUR (Purification or recovery); ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation) (Isolation and identification of bromfenac glucoside from rat bile)

RN 212266-82-5 CAPLUS

CN Benzenecetic acid, 3-(4-bromobenzoyl)-2-(β -D-glucopyranosylamino)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1979:48166 CAPLUS

DN 90:48166

OREF 90:7589a,7592a

TI Synthesis of Aminoglucuronides in rats. Relation of the process to the physicochemical properties of the substrate

AU Golovenko, N. Ya.

CS I. I. Mechnikov State Univ., Odessa, USSR


SO Voprosy Meditsinskoi Khimii (1978), 24(5), 676-8

CODEN: VMEDKAM; ISSN: 0042-8809

DT Journal

LA Russian

GI



AB Administration of 5-substituted (amino, Me, unsubstituted, and chloro derivs.) 2-aminobenzophenones (I [18330-94-4], II [17852-28-7], III [2835-77-0], and IV [719-59-5], resp.), which are metabolites of benzodiazepine tranquilizers, to rats resulted in their conjugation with glucuronic acid with the formation of N-glucuronides. The rates of urinary excretion of the nonconjugated compds. were in the order: II > III > I > IV, whereas the rates of excretion of the glucuronides were: II > I > III > IV. The derivs. differed with respect to the values of their Hammett consts., lipophilicity, and basicity. A correlation was found between the physicochem. properties of the derivs. and the amts. of glucuronides excreted in the urine.

IT 69038-25-1


RL: FORM (Formation, nonpreparative)

(formation of, from aminobenzophenone, urinary excretion in relation to)

RN 69038-25-1 CAPLUS

CN β -D-Glucopyranuronic acid, 1-[(2-benzoylphenyl)amino]-1-deoxy- (CA INDEX NAME)

Absolute stereochemistry.



IT 69038-26-2 69038-27-3


RL: FORM (Formation, nonpreparative)

(formation of, from diaminobenzophenone, urinary excretion in relation to)

RN 69038-26-2 CAPLUS

CN β -D-Glucopyranuronic acid, 1-[(2-benzoyl-4-methylphenyl)amino]-1-deoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 69038-27-3 CAPLUS

CN β -D-Glucopyranuronic acid, 1-[(2-benzoyl-4-chlorophenyl)amino]-1-deoxy- (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1978:98910 CAPLUS

DN 88:98910

ORF 88:15405a,15408a

TI Biliary excretion of nitrazepam and its metabolites in rats

AU Golovenko, N. Ya.; Karaseva, T. L.

CS Odess. Gos. Univ., Odessa, USSR


SO Farmakologiya i Toksikologiya (Moscow) (1978), 41(1), 17-19

CODEN: FATOAO; ISSN: 0014-8318

DT Journal

LA Russian

GI



AB Nitrazepam (I) [146-22-5] (10 mg/kg) injected i.v. into rats was excreted in the bile as free and conjugated metabolites. Metabolites included the free amine [4928-02-3] and acetamide [4928-03-4] and N- and O-glucuronides.

IT 65846-31-3

RL: BIOL (Biological study)
(as nitrazepam metabolite)

RN 65846-31-3 CAPLUS

CN β -D-Glucopyranuronic acid, 1-[(2-benzoyl-4-nitrophenyl)amino]-1-deoxy-
(CA INDEX NAME)

Absolute stereochemistry.

